FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/07/070779 [Registered on: 18/07/2024] Trial Registered Prospectively
Last Modified On: 13/08/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Cosmeceuitcal ]  
Study Design  Other 
Public Title of Study   Safety check of products on human volunteers 
Scientific Title of Study   To evaluate the dermatological safety of investigational products through primary irritation patch test on healthy human volunteers with varied skin  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
D01-6Q57-ZC-JY24; Version: Final 01;04/07/2024  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Pooja Yadav 
Designation  Principal Investigator 
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd. 
Address  Sea Breeze Building, 9th Floor, AppaSaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai,

Mumbai
MAHARASHTRA
400025
India 
Phone  02243349191  
Fax    
Email  investigators@mascotspincontrol.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Pooja Yadav 
Designation  Principal Investigator 
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd. 
Address  Sea Breeze Building, 9th Floor, AppaSaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai,


MAHARASHTRA
400025
India 
Phone  02243349191  
Fax    
Email  investigators@mascotspincontrol.in  
 
Details of Contact Person
Public Query
 
Name  Dr Mohit Lalvani 
Designation  Study Director 
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd. 
Address  Sea Breeze Building, 9th Floor, AppaSaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai,

Mumbai
MAHARASHTRA
400025
India 
Phone  02243349191  
Fax    
Email  mohit.CTRI@gmail.com  
 
Source of Monetary or Material Support  
ITC LIMITED, ITC Life Sciences and Technology Centre,No. 3, st Main Road, Peenya Industrial Area, I Phase Peenya, Bangalore – 560058, INDIA 
 
Primary Sponsor  
Name  ITC LIMITED 
Address  ITC Life Sciences and Technology Centre,No. 3, st Main Road, Peenya Industrial Area, I Phase Peenya, Bangalore – 560058, INDIA 
Type of Sponsor  Other [FMCG] 
 
Details of Secondary Sponsor  
Name  Address 
NIL   NA 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Pooja Yadav  Mascot Spincontrol India Pvt. Ltd.   Sea Breeze Building, 9th Floor, AppaSaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai
Mumbai
MAHARASHTRA 
02243349191

investigators@mascotspincontrol.in 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Ethos- An Institutional Ethics committee (Mumbai)   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  with varied skin type  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  1% Sodium Lauryl Sulphate (SLS) - Positive control   A single application of about 0.04ml of 1% SLS, prepared in distilled water is applied under occlusion for 24hrs on the subjects back  
Intervention  13-133  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  13-139A  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  13-139B  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  13-139C  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  13-139D  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  13-151A  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back 
Intervention  13-151B  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  13-151C  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back 
Intervention  13-151D  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  15-174A  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  15-174B  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  15-174C  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  15-174D  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-046A  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-046B  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-046C  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-046D  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-049  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-054A  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-054B  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-054C  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  17-054D  A single application of about 0.04ml of product is applied under semi-occlusion for 24hrs on the subjects back. 
Intervention  HCL-38-19  A single application of about 0.04ml of 0.4% V/V of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back.  
Comparator Agent  Negative Control (0.9% Isotonic Saline Solution)   A single application of about 0.04ml of 0.9% Isotonic Saline, is applied under occlusion for 24hrs on the subjects back.  
Comparator Agent  Negative Control (Distilled Water)   A single application of about 0.04ml of Distilled Water, is applied under occlusion for 24hrs on the subjects back.  
Comparator Agent  Positive control (3% w/w SLS)   A single application of about 0.04ml of 3% SLS, prepared in distilled water is applied under occlusion for 24hrs on the subjects back  
Intervention  TSP145-127  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back.  
Intervention  TSP145-128  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back. 
Intervention  TSP145-129  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back. 
Intervention  TSP145-130  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back. 
Intervention  TSP146-067  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back.  
Intervention  TSP146-117  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back. 
Intervention  TSP15398-B29L2A MFD-092023  A single application of about 0.04ml of 8% w/w of product prepared in distilled water, is applied under occlusion for 24hrs on the subjects back. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1)Female and male Asian Indian subjects.
2)Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
3)Subjects who have not participated in a similar investigation in the past eight weeks.
4)Subjects representing varied skin types 
 
ExclusionCriteria 
Details  1)For female : Being pregnant or breastfeeding or having stopped to breastfeed in the past three months, Having refused to give his/her assent by signing the consent form, Taking part in another study liable to interfere with this study Being diabetic,Being asthmatic,Having eczema, oriasis, lichen plan, vitiligo whatever the considered area, Having disorder of the healing (whatever the considered area),Having a rhinitis, allergic conjunctivitis or rhinosinusitis.
2) Having eczema, psoriasis, lichen planus, vitiligo etc. in the concerned area.
3)Having healing disorder in the concerned area.
4)Having rhinitis, allergic conjunctivitis, or rhino sinusitis.
5) Having an allergy to perfumes and/or preservatives in cosmetic products.
6)Having an allergy to plaster / adhesives used in plaster.
7) Having a food allergy.
8)Having a cardiovascular pathology that requires beta blocking treatments.
9)Having immunosuppressive drugs, such as cyclophosphamide, methotrexate, azathioprine, etc.
10)Taking a retinoid-based treatment by general or oral route.
11)Taking specific treatment on the back.
12) Having taken an anti-histaminic treatment in the last 2 weeks preceding the start of the study.
13)Having miliaria (prickly heat) on the back.
14) Presenting too many neavi on the back.
15) Having high pilosity on the back.  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Outcome TimePoints
Dermatological safety / Irritation potential on skin  
Baseline,0 hrs,24 hrs & 7 days  
 
Secondary Outcome  
Outcome  TimePoints 
Nil  NA 
 
Target Sample Size   Total Sample Size="26"
Sample Size from India="26" 
Final Enrollment numbers achieved (Total)= "26"
Final Enrollment numbers achieved (India)="26" 
Phase of Trial   N/A 
Date of First Enrollment (India)   27/07/2024 
Date of Study Completion (India) 01/08/2024 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="0"
Days="9" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Single application, Semi-occlusive and closed occlusive patch study.

Objective: To evaluate the dermatological safety of investigational products through primary irritation patch test on healthy human volunteers with varied skin.

Duration of study: 9 days [3days and T8 (Evaluation of test sites by Dermatologist and Subject post 1 week of patch removal) visit is scheduled to monitor follow up reactions]

Population 26 healthy subjects(13 males + 13 females)

 
Close